BELGRADE, Mont., May 6, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025.
Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results.
Conference Details:
Conference Date: Monday, May 12, 2025
Conference Time: 4:30 PM ET
Conference dial-in: 888-506-0062
International dial-in: 973-528-0011
Passcode: 828748
Conference Call Name: Xtant Medical Q1 2025 Financial Results
Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/52428
Following the live call, a replay will be available on the Company's website, https://xtantmedical.com/, under "Investor Info."
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of "honoring the gift of donation so that our patients can live as full and complete a life as possible" is the driving force behind our company. Xtant Medical Holdings, Inc. ( www.xtantmedical.com ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States , and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Last Trade: | US$0.51 |
Daily Change: | -0.03 -5.96 |
Daily Volume: | 55,614 |
Market Cap: | US$70.200M |
November 12, 2024 September 23, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load